Apostolova Liana G, Haider Janelle M, Goukasian Naira, Rabinovici Gil D, Chételat Gael, Ringman John M, Kremen Sarah, Grill Joshua D, Restrepo Lucas, Mendez Mario F, Silverman Daniel H
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Radiological Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA.
Department of Neurology, Cedar-Sinai Medical Center, Los Angeles, CA, USA.
Alzheimers Dement (Amst). 2016 Dec 18;5:15-22. doi: 10.1016/j.dadm.2016.12.001. eCollection 2016.
The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established.
Fifty-three cognitively impaired patients with clinical F-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and test were used to compare demographic characteristics and clinical outcomes as appropriate.
Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group.
The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.
淀粉样蛋白成像的合理使用标准（AUC）的效用尚未确立。
53例有临床F-氟代硼替佐米成像的认知障碍患者被分为早发型和晚发型，以及AUC一致或AUC不一致。根据情况使用卡方统计和检验来比较人口统计学特征和临床结果。
早发型患者更可能为淀粉样蛋白阳性。晚发型病例中诊断改变更频繁。早发型病例中治疗改变更常见。AUC一致和AUC不一致的病例淀粉样蛋白阳性率相当。我们发现AUC一致组与AUC不一致组相比，治疗改变率没有差异。
淀粉样蛋白成像在早发型组中的主要作用是确认临床怀疑的病因，在晚发型组中是检测淀粉样蛋白阴性病例。早发型病例中治疗改变率显著更高。
